Filing Flows › Industries › Health Care › In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances SIC 2835
15 companies filing with the SEC under SIC 2835. Median revenue growth +2% year on year in Q3 2026 (middle half -8% to +10%, 9 companies). The growth model expects the industry's combined revenue to grow +8% in Q3 2026. 3 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- MYGN → Medicare & Medicaid 10% of the supplier's revenue, $82.5M
- TMO → IDXX
- BIO → IMDX
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +8.2% | $2.9B | $2.6B – $3.1B |
| Q4 2026 | +10.6% | $3.0B | $2.6B – $3.3B |
| Q1 2027 | +11.7% | $2.9B | $2.6B – $3.2B |
| Q2 2027 | +12.1% | $3.0B | $2.6B – $3.4B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| IDXX Idexx Laboratories | $1.2B | +10% | mature |
| QDEL QuidelOrtho | $619M | -12% | contraction |
| LNTH Lantheus Holdings | $390M | +2% | mature |
| NEOG Neogen | $223M | +7% | mature |
| MYGN Myriad Genetics | $203M | -1% | mature |
| TKNO Alpha Teknova | $12.7M | +22% | expansion |
| ICCC Immucell | $7.2M | — | deceleration |
| NTLA Intellia Therapeutics | $7.2M | -48% | contraction |
| AWHL Aspira Women's Health | $2.0M | — | contraction |
| BMRA Biomerica | $1.3M | -8% | contraction |
| Ionetix | $1.2M | — | reacceleration |
| VNRX Volitionrx | $399K | — | mature |
| IMDX Insight Molecular Diagnostics | $239K | — | transition |
| CLDX Celldex Therapeutics | $22K | — | transition |
| CDIO Cardio Diagnostics Holdings | $4K | +26% | reacceleration |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.